Literature DB >> 22072582

Inverse association between glutathione peroxidase activity and both selenium-binding protein 1 levels and Gleason score in human prostate tissue.

Anita Jerome-Morais1, Margaret E Wright, Rui Liu, Wancai Yang, Matthew I Jackson, Gerald F Combs, Alan M Diamond.   

Abstract

BACKGROUND: Data from human epidemiological studies, cultured mammalian cells, and animal models have supported a potentially beneficial role of selenium (Se) in prostate cancer prevention. In addition, Se-containing proteins including members of the glutathione peroxidase (GPx) family and Selenium-Binding Protein 1 (SBP1) have been linked to either cancer risk or development. For example, SBP1 levels are typically reduced in tumors compared to non-cancerous tissue, with the degree of reduction associated with increasingly poor clinical outcome.
METHODS: In order to investigate inter-relationships between blood and tissue Se levels and GPx activity, tissue SBP1 levels, and disease aggressiveness using the Gleason score, we measured levels of selenium and selected selenoproteins in fasting serum and histologically normal prostate tissues obtained from 24 men undergoing radical prostatectomy for the treatment of localized prostate cancer.
RESULTS: GPx enzyme activity was inversely correlated with SBP1 levels in prostate tissue as determined by densitometry of Western blots obtained using anti-SBP1 antibodies [partial Spearman's correlation coefficients and corresponding P-values overall and in African-Americans = -0.42 (0.08) and -0.53 (0.10), respectively], which is consistent with previous observations in cultured cells and mice. Of particular interest was the positive correlation between tissue GPx activity and Gleason score, with this relationship achieving statistical significance among African-Americans (r = 0.67, P = 0.02).
CONCLUSION: These studies support the continued investigation of the role of Se and selenoproteins in prostate cancer prevention, development, and prognosis.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072582      PMCID: PMC3288333          DOI: 10.1002/pros.21506

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  25 in total

1.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis.

Authors:  D M Hockenbery; Z N Oltvai; X M Yin; C L Milliman; S J Korsmeyer
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

2.  Enhanced skin carcinogenesis in transgenic mice with high expression of glutathione peroxidase or both glutathione peroxidase and superoxide dismutase.

Authors:  Y P Lu; Y R Lou; P Yen; H L Newmark; O I Mirochnitchenko; M Inouye; M T Huang
Journal:  Cancer Res       Date:  1997-04-15       Impact factor: 12.701

3.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

4.  Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.

Authors:  Siu T Yuen; Helen Davies; Tsun L Chan; Judy W Ho; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Wendy W Tsui; Annie S Chan; P Andrew Futreal; Michael R Stratton; Richard Wooster; Suet Y Leung
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin-treated human breast carcinoma cells.

Authors:  V Gouazé; M E Mirault; S Carpentier; R Salvayre; T Levade; N Andrieu-Abadie
Journal:  Mol Pharmacol       Date:  2001-09       Impact factor: 4.436

7.  Increased glutathione peroxidase activity in a human sarcoma cell line with inherent doxorubicin resistance.

Authors:  B L Samuels; J L Murray; M B Cohen; A R Safa; B K Sinha; A J Townsend; M A Beckett; R R Weichselbaum
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

8.  Characterization of mammalian selenoproteomes.

Authors:  Gregory V Kryukov; Sergi Castellano; Sergey V Novoselov; Alexey V Lobanov; Omid Zehtab; Roderic Guigó; Vadim N Gladyshev
Journal:  Science       Date:  2003-05-30       Impact factor: 47.728

9.  Evidence for two selenium-binding proteins distinct from glutathione peroxidase in mouse liver.

Authors:  M P Bansal; C J Oborn; K G Danielson; D Medina
Journal:  Carcinogenesis       Date:  1989-03       Impact factor: 4.944

10.  Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas.

Authors:  Guoan Chen; Hong Wang; Charles T Miller; Dafydd G Thomas; Tarek G Gharib; David E Misek; Thomas J Giordano; Mark B Orringer; Samir M Hanash; David G Beer
Journal:  J Pathol       Date:  2004-03       Impact factor: 7.996

View more
  23 in total

Review 1.  Molecular cross-talk between members of distinct families of selenium containing proteins.

Authors:  Emmanuel Ansong; Wancai Yang; Alan M Diamond
Journal:  Mol Nutr Food Res       Date:  2013-11-13       Impact factor: 5.914

2.  Selenium, nickel, and calcium levels in cancerous and non-cancerous prostate tissue samples and their relation with some parameters.

Authors:  İlker Çelen; Talha Müezzinoğlu; O Yavuz Ataman; Sezgin Bakırdere; Mehmet Korkmaz; Nalan Neşe; Feriye Şenol; Murat Lekili
Journal:  Environ Sci Pollut Res Int       Date:  2015-04-30       Impact factor: 4.223

3.  Variation in selenoenzyme genes and prostate cancer risk and survival.

Authors:  Milan S Geybels; Carolyn M Hutter; Erika M Kwon; Elaine A Ostrander; Rong Fu; Ziding Feng; Janet L Stanford; Ulrike Peters
Journal:  Prostate       Date:  2012-11-09       Impact factor: 4.104

4.  Selenium- or Vitamin E-Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT.

Authors:  Philip W Kantoff; Lorelei A Mucci; June M Chan; Amy K Darke; Kathryn L Penney; Catherine M Tangen; Phyllis J Goodman; Gwo-Shu Mary Lee; Tong Sun; Sam Peisch; Alex M Tinianow; James M Rae; Eric A Klein; Ian M Thompson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-05-06       Impact factor: 4.254

5.  Predicting dedifferentiation in liposarcoma: a proteomic approach.

Authors:  Colt M McClain; David B Friedman; Tahar Hajri; Cheryl M Coffin; Justin M M Cates
Journal:  Virchows Arch       Date:  2013-05-26       Impact factor: 4.064

Review 6.  Does a role for selenium in DNA damage repair explain apparent controversies in its use in chemoprevention?

Authors:  Soumen Bera; Viviana De Rosa; Walid Rachidi; Alan M Diamond
Journal:  Mutagenesis       Date:  2012-11-30       Impact factor: 3.000

7.  Distribution and inhibition effect of Seleno-L-Methionine on 4T1 mouse mammary carcinoma.

Authors:  Hongjiao Song; Xiaomin Ren; Ping Liu
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2015-08-15

8.  The effects of selenium and the GPx-1 selenoprotein on the phosphorylation of H2AX.

Authors:  A Jerome-Morais; S Bera; W Rachidi; P H Gann; A M Diamond
Journal:  Biochim Biophys Acta       Date:  2013-03-18

9.  Quantitative proteomic analysis reveals that anti-cancer effects of selenium-binding protein 1 in vivo are associated with metabolic pathways.

Authors:  Qi Ying; Emmanuel Ansong; Alan M Diamond; Zhaoxin Lu; Wancai Yang; Xiaomei Bie
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

Review 10.  The subcellular location of selenoproteins and the impact on their function.

Authors:  Alan M Diamond
Journal:  Nutrients       Date:  2015-05-22       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.